Bergeon Julie A, Toth Istvan
School of Molecular and Microbial Sciences (SMMS), The University of Queensland, St. Lucia, Qld 4072, Australia.
Bioorg Med Chem. 2007 Nov 15;15(22):7048-57. doi: 10.1016/j.bmc.2007.07.040. Epub 2007 Aug 22.
The dipeptide l-Glu-l-Trp-OH (IM862) is currently under development for the treatment of certain cancers and immuno-deficiency disorders. However, due to its highly hydrophilic character, IM862 demonstrates low permeability across biological membranes, including the gastro-intestinal track, which makes it not orally available. In this study, the effect of lipid conjugation on the stability and intestinal permeability of the IM862 amide derivative l-Glu-l-Trp-NH(2) was investigated using enzymatic extracts and monolayers of Caco-2 cells, respectively. A series of eleven novel lipopeptide analogues of l-Glu-l-Trp-NH(2) was synthesized using tert-butyloxycarbonyl or 9-fluorenylmethoxycarbonyl solid-phase peptide synthesis. In vitro assays demonstrated an improved stability to proteolytic enzymes and increased intestinal permeability for several conjugates, thereby supporting the hypothesis that lipidation may provide a means to enable the oral administration of IM862.
二肽l-谷氨酸-l-色氨酸-OH(IM862)目前正在研发用于治疗某些癌症和免疫缺陷疾病。然而,由于其高度亲水性,IM862在包括胃肠道在内的生物膜上表现出低渗透性,这使其无法口服。在本研究中,分别使用酶提取物和Caco-2细胞单层研究了脂质缀合对IM862酰胺衍生物l-谷氨酸-l-色氨酸-NH(2)稳定性和肠道渗透性的影响。使用叔丁氧羰基或芴甲氧羰基固相肽合成法合成了一系列11种新型的l-谷氨酸-l-色氨酸-NH(2)脂肽类似物。体外试验表明,几种缀合物对蛋白水解酶的稳定性有所提高,肠道渗透性增加,从而支持了脂质化可能提供一种使IM862能够口服给药的方法这一假设。